Biomedical sciences industry is the fourth pillar of the country’s manufacturing economy and is extensively fostering local R&D and startups to boost innate innovations. In 2016, the Singapore government committed to a S$4 billion budget to drive research and commercialisation activities in the health and biomedical sciences sector. Further supporting the initiative, Enterprise Singapore Enterprise(SG), the statutory board of the Singapore Ministry of Trade and Industry plays a vital role in supporting local startup ecosystems. In an interaction with BioSpectrum Asia, Audrey Lok, Director of Healthcare and Biomedical, EnterpriseSG shared insights on its role in promoting Singapore as an Asia-Pacific hub for startups and innovations. Edited excerpts;
How conducive is Singapore's startup ecosystem for fostering bioscience initiatives and empowering entrepreneurship?
COVID-19 has rapidly accelerated the pace of medical innovation and transformation, and it comes as no surprise that we now have more investors and startups in this sector. As of 2021, 400 biomedical startups and SMEs in Singapore prioritise innovative solutions that address today’s healthcare needs or ones that address the pandemic. 1.3 billion in biomedical investments across 40 deals have been recorded in the same year.
A part of this success can be attributed to the thriving ecosystem built upon strong public-private partnerships. Our public healthcare clusters have enabled many healthcare and biomedical startups to embrace innovation, by tapping the clinical strengths and expertise of our healthcare system to refine, develop and testbed solutions. In fact, they have been supporting more than 100 industry engagements and facilitations every year. They are also critical partners who identify
Esta historia es de la edición January 2023 de BioSpectrum Asia.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición January 2023 de BioSpectrum Asia.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.
